鈣激活鉀通道蛋白 α 1抗體 返回列表頁

英文名稱 BK channel
中文名稱 鈣激活鉀通道蛋白 α 1抗體
別    名 Maxi Potassium channel alpha; bA205K10.1; BK channel; BKCa channels; BKCA alpha; BKCA alpha subunit; BKTM; Calcium activated potassium channel subfamily M subunit alpha 1; Calcium activated potassium channel subunit alpha 1; DKFZp686K1437; Drosophila slowpoke like; hSlo; K(VCA)alpha; KCa1.1; KCNMA 1; KCNMA; KCNMA1; Large conductance calcium activated potassium channel subfamily M alpha member 1; Maxi K; Maxi K channel; MaxiK; Potassium large conductance calcium activated channel subfamily M alpha member 1; SAKCA; Slo 1; SLO alpha; SLO; Slo homolog; Slo1; Slowpoke homolog; Stretch activated Kca channel; KCMA1_HUMAN.
鈣激活鉀通道蛋白 α 1抗體 
說 明 書 0.1ml  0.2ml  
研究領(lǐng)域 通道蛋白  
抗體來源 Rabbit
克隆類型 Polyclonal
交叉反應(yīng) Human, Mouse, Rat, Dog, Pig, Cow, Horse, Rabbit, Sheep, 
產(chǎn)品應(yīng)用 IHC-P=1:100-500 IHC-F=1:100-500 （石蠟切片需做抗原修復(fù)）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量 137kDa
細胞定位 細胞膜 
性    狀 Lyophilized or Liquid
濃    度 1mg/1ml
免 疫 原 KLH conjugated synthetic peptide derived from human BK channel (1197-1236aa)
亞    型 IgG
純化方法 affinity purified by Protein A
儲 存 液 0.01M PBS, pH 7.4 with 10 mg/ml BSA and 0.1% Sodium azide
保存條件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
鈣激活鉀通道蛋白 α 1抗體產(chǎn)品介紹 background:
MaxiK channels are large conductance, voltage and calcium-sensitive potassium channels which are fundamental to the control of smooth muscle tone and neuronal excitability. MaxiK channels can be formed by 2 subunits: the pore-forming alpha subunit, which is the product of this gene, and the modulatory beta subunit. Intracellular calcium regulates the physical association between the alpha and beta subunits. Alternatively spliced transcript variants encoding different isoforms have been identified. [provided by RefSeq, Jul 2008].

Function:
Potassium channel activated by both membrane depolarization or increase in cytosolic Ca(2+) that mediates export of K(+). It is also activated by the concentration of cytosolic Mg(2+). Its activation dampens the excitatory events that elevate the cytosolic Ca(2+) concentration and/or depolarize the cell membrane. It therefore contributes to repolarization of the membrane potential. Plays a key role in controlling excitability in a number of systems, such as regulation of the contraction of smooth muscle, the tuning of hair cells in the cochlea, regulation of transmitter release, and innate immunity. In smooth muscles, its activation by high level of Ca(2+), caused by ryanodine receptors in the sarcoplasmic reticulum, regulates the membrane potential. In cochlea cells, its number and kinetic properties partly determine the characteristic frequency of each hair cell and thereby helps to establish a tonotopic map. Kinetics of KCNMA1 channels are determined by alternative splicing, phosphorylation status and its combination with modulating beta subunits. Highly sensitive to both iberiotoxin (IbTx) and charybdotoxin (CTX).

Subunit:
Homotetramer.

Subcellular Location:
Membrane; Multi-pass membrane protein.

Tissue Specificity:
Widely expressed. Except in myocytes, it is almost ubiquitously expressed.

Post-translational modifications:
Phosphorylated (Probable). Phosphorylation by kinases such as PKA and/or PKG. In smooth muscles, phosphorylation affects its activity.

DISEASE:
Defects in KCNMA1 are the cause of generalized epilepsy and paroxysmal dyskinesia (GEPD) [MIM:609446]. Epilepsy is one of the most common and debilitating neurological disorders. Paroxysmal dyskinesias are neurological disorders characterized by sudden, unpredictable, disabling attacks of involuntary movement often requiring life-long treatment. The coexistence of epilepsy and paroxysmal dyskinesia in the same individual or family is an increasingly recognized phenomenon. Patients manifest absence seizures, generalized tonic-clonic seizures, paroxysmal nonkinesigenic dyskinesia, involuntary dystonic or choreiform movements. Onset is usually in childhood and patients may have seizures only, dyskinesia only, or both.

Similarity:
Belongs to the potassium channel family. Calcium-activated (TC 1.A.1.3) subfamily. KCa1.1/KCNMA1 sub-subfamily.
Contains 1 RCK N-terminal domain.

Gene ID:
3778

Database links:

Entrez Gene: 3778 Human

Entrez Gene: 16531 Mouse

Entrez Gene: 83731 Rat

Omim: 600150 Human

SwissProt: Q12791 Human

SwissProt: Q08460 Mouse

SwissProt: Q62976 Rat

Unigene: 144795 Human

Unigene: 343607 Mouse

Unigene: 486347 Mouse

Unigene: 30616 Rat鈣激活鉀通道蛋白 α 1抗體xy-2251R A RafA-Raf抗體
xy-3371R Phospho-A Raf(Ser299)磷酸化A-Raf抗體
xy-9517R AMPD3紅細胞腺苷脫氨酶3抗體
xy-2410R ABP雄激素結(jié)合蛋白抗體
xy-1576R ALR肝再生增強因子抗體
xy-0112R Amyloid Precursor ProteinAPP/ABPP淀粉樣肽前體蛋白抗體
xym-1621M AFP(A2)甲胎蛋白單克隆抗體（包被）
xym-1622M AFP(A4)甲胎蛋白單克隆抗體(檢測)
xy-1477R ARFIP1 ADP核糖基化因子結(jié)合蛋白1抗體
xy-1416R AHR芳香烴受體抗體
xy-1528R ATRN吸引素抗體
xy-1627R ABCA1腺苷三磷酸結(jié)合盒轉(zhuǎn)運體A1抗體
xy-2056R AKT2蛋白激酶B2
xy-0677R Angiopoietin 2血管生成素2抗體
xy-0114R Aromatase芳香化酶/細胞色素P450/雌激素合成酶抗體
xy-1456R Adenosine Receptor A2a腺苷A2A受體抗體
xy-1473R AKAP95蛋白激酶A錨定蛋白95抗體
xy-4189R ASBT頂膜鈉依賴性膽鹽轉(zhuǎn)運體蛋白抗體
xy-4195R ADAM8去整合素樣金屬蛋白酶8抗體
xy-11386R AADACL3芳香乙酰胺脫乙?；笜拥鞍?抗體
xy-12444R ACN9ACN9蛋白抗體
xy-2167R ADAR1 (N-terminus)雙鏈RNA腺苷酸脫氨基酶抗體（N端）
xy-2771R AMPK alpha 2腺苷單磷酸活化蛋白激酶α2抗體
xy-2778R ADK腺苷酸激酶抗體
xy-13780R A2ML1α2巨球蛋白樣蛋白1抗體 α2ML1
xy-13814R APR3細胞凋亡相關(guān)蛋白3抗體